STML-ELA-022 A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Stemline Therapeutics
This research study is being done to find out if elacestrant is safe and tolerable when given in combination with one of the following study drugs, approved in the treatment of advanced breast cancer: alpelisib, everolimus, palbociclib, abemaciclib, or ribociclib. Researchers will also look at what effect elacestrant (with the other study drugs) has tumor(s).
Enrollment Form
This study is currently enrolling.